References
- Aslan AT, Akova M. The role of colistin in the era of new β-lactam/β-lactamase inhibitor combinations. Antibiotics. 2022 Feb;11(2):277. https://doi.org/10.3390/antibiotics11020277
- Bae MH, Kim MS, Kim TS, Kim S, Yong D, Ha GY, Ryoo NH, Uh Y, Shin JH, Lee HS, et al. Changing epidemiology of pathogenic bacteria over the past 20 years in Korea. J Korean Med Sci. 2023 Mar;38(10):e73. https://doi.org/10.3346/jkms.2023.38.e73
- Cheong HS, Park KH, Kim B, Eun BW, Kim HS, Kim YC, Lee H, Jeong SJ, Moon C, Kim SW, et al. Developing core elements and checklist items for implementing antimicrobial stewardship programs in Korean general hospitals: A modified delphi survey. Infect Chemother. 2023 Mar;55(1):59–68. https://doi.org/10.3947/ic.2022.0169
- Cheong HS, Park KH, Kim HB, Kim SW, Kim B, Moon C, Lee MS, Yoon YK, Jeong SJ, Kim YC, et al.; Korean Society for Antimicrobial Therapy; Korean Society of Infectious Diseases; Korean Society for Healthcare-associated Infection Control and Prevention; Korean Society of Pediatric Infectious Diseases, The Korean Society of Health-system Pharmacists. Core elements for implementing antimicrobial stewardship programs in Korean general hospitals. Infect Chemother. 2022 Dec;54(4):637–673. https://doi.org/10.3947/ic.2022.0171
- Choi YJ, Kim YA, Junglim K, Jeong SH, Shin JH, Shin KS, Shin JH, Kim YR, Kim HS, Uh Y, et al. Emergence of NDM-1-producing Pseudomonas aeruginosa sequence type 773 clone: Shift of carbapenemase molecular epidemiology and spread of 16S rRNA methylase genes in Korea. Ann Lab Med. 2023 Mar;43(2):196–199. https://doi.org/10.3343/alm.2023.43.2.196
- Christophy R, Osman M, Mallat H, Achkar M, Ziedeh A, Moukaddem W, Dabboussi F, Hamze M. Prevalence, antibiotic susceptibility and characterization of antibiotic resistant genes among carbapenem-resistant Gram-negative bacilli and yeast in intestinal flora of cancer patients in North Lebanon. J Infect Public Health. 2017 Nov-Dec;10(6):716–720. https://doi.org/10.1016/j. jiph.2016.10.009
- Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M, Irani P. Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa. Antibiotics. 2021 Sep 18;10(9):1126. https://doi.org/10.3390/antibiotics10091126
- Hammoudi Halat D, Ayoub Moubareck C. The intriguing carbapenemases of Pseudomonas aeruginosa: Current status, genetic profile, and global epidemiology. Yale J Biol Med. 2022 Dec;95(4):507-515.
- Hernández-Jiménez P, López-Medrano F, Fernández-Ruiz M, Silva JT, Corbella L, San-Juan R, Lizasoain M, Díaz-Regañón J, Viedma E, Aguado JM. Risk factors and outcomes for multidrug resistant Pseudomonas aeruginosa infection in immunocompromised patients. Antibiotics. 2022 Oct;11(11):1459. https://doi.org/10.3390/antibiotics11111459
- Huh K, Chung DR, Ha YE, Ko JH, Kim SH, Kim MJ, Huh HJ, Lee NY, Cho SY, Kang CI, et al; Korean Antimicrobial Resistance Surveillance Network (KARS-Net) Investigators. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: Retrospective analysis of nationwide surveillance data. Clin Infect Dis. 2020 Dec;71(9):e487–e496. https://doi.org/10.1093/cid/ciaa084
- Jeong S, Jeon K, Lee N, Park MJ, Song W. Changing genotypic distribution, antimicrobial susceptibilities, and risk factors of urinary tract infection caused by carbapenemase-producing Pseudomonas aeruginosa. Ann Lab Med. 2024 Jan;44(1):38–46. https://doi.org/10.3343/alm.2024.44.1.38
- Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, et al.; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018 Nov;67(12):1803–1814. https://doi.org/10.1093/cid/ciy378
- Kang JS, Moon C, Mun SJ, Lee JE, Lee SO, Lee S, Lee SH. Antimicrobial susceptibility trends and risk factors for antimicrobial resistance in Pseudomonas aeruginosa bacteremia: 12-year experience in a tertiary hospital in Korea. J Korean Med Sci. 2021 Nov;36(43):e273. https://doi.org/10.3346/jkms.2021.36.e273
- Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: Results from the inform global surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2018 Jun;62(7):e02569-17. https://doi.org/10.1128/aac.02569-17
- Karruli A, Catalini C, D’Amore C, Foglia F, Mari F, Harxhi A, Galdiero M, Durante-Mangoni E. Evidence-based treatment of Pseudomonas aeruginosa infections: A critical reappraisal. Antibiotics. 2023 Feb;12(2):399. https://doi.org/10.3390/antibiotics12020399
- Kim YJ, Huh HJ, Sung H. Challenges of carbapenem-resistant Pseudomonas aeruginosa in infection control and antibiotic management. Ann Lab Med. 2024 Jan;44(1):1–2. https://doi.org/10.3343/alm.2024.44.1.1
- Lee HJ, Lee DG. Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria. Korean J Intern Med. 2022 Mar;37(2):271–280. https://doi.org/10.3904/kjim.2021.527
- Lee YL, Ko WC, Hsueh PR. Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific region: Results from the antimicrobial testing leadership and surveillance (ATLAS) program, 2015-2019. Antimicrob Agents Chemother. 2022 Feb;66(2):e0200021. https://doi.org/10.1128/aac.02000-21
- Mack AR, Hujer AM, Mojica MF, Taracila MA, Feldgarden M, Haft DH, Klimke W, Prasad AB, Bonomo RA. β-Lactamase diversity in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2025 Mar;69(3):e0078524. https://doi.org/10.1128/aac.00785-24
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x
- Marashi SMA, Nikkhahi F, Hamedi D, Shahbazi G. Isolation, characterization and in vitro evaluation of specific bacteriophages targeting extensive drug resistance strains of Pseudomonas aeruginosa isolated from septic burn wounds. Infect Chemother. 2022 Mar;54(1):153–164. https://doi.org/10.3947/ic.2021.0132
- Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis. 2019 Jan;68(3):519–524. https://doi.org/10.1093/cid/ciy576
- Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011 May;70(1):119–123. https://doi.org/10.1016/j.diag-microbio.2010.12.002
- Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents. 2015 Jun;45(6):568–585. https://doi.org/10.1016/j.ijantimi-cag.2015.03.001
- Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018 Jul;7:79. https://doi.org/10.1186/s13756-018-0370-9 =
- Sader HS, Huband MD, Castanheira M, Flamm RK. Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States. Antimicrob Agents Chemother. 2017 Feb;61(3):e02252-16. https://doi.org/10.1128/aac.02252-16
- Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:2475067. https://doi.org/10.1155/2016/2475067
- Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, Giske CG, Turnidge J. Clinical and Laboratory Standards Institute and European committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020 Dec 3;71(9):e523–e529. https://doi.org/10.1093/cid/ciaa121
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infectionsClin Infect Dis. 2023 Jul 18:ciad428. https://doi.org/10.1093/cid/ciad428
- Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022 Dec;11(1):811–814. https://doi.org/10.1080/22221751. 2022.2048972
- Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song JH, Patel R. Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother. 2017 Dec;62(1):e01970–17. https://doi.org/10.1128/aac.01970-17